Escaping pilot purgatory: What it really takes to scale agentic AI
Artificial intelligence has moved well beyond the experimentation phase. But despite showing initial promise, most AI projects in life sciences fail to make it out of the pilot stage.
The disconnect has become so familiar that it has earned its own nickname: "pilotitis", where organisations continue to invest in proofs-of-concept, only to find that success in a controlled environment rarely translates into day-to-day operations.
In an area where technology is advancing at a rapid pace, it’s easy to assume that the AI tool is the root cause of the problem; however, that may not be the case. Companies like Axtria, which have successfully navigated the transition from pilot to enterprise, have learned that technology is just one part of an intricate puzzle that must align if agentic AI tools are to succeed at scale.
Stop treating AI like traditional software
The first few weeks of an agentic AI pilot can be deceptively reassuring. Within the controlled pilot environment, where data is carefully selected and tasks are well-defined, the AI agent performs exactly as intended. But, as many organisations have discovered, success in isolation doesn’t always translate to success at scale.
“An LLM is by its very nature a probabilistic model. It is not a deterministic model.”
That’s because day-to-day operations are a lot more complicated than the conditions established in the pilot environment. And, as such, promising ideas remain trapped in a familiar cycle of pilot purgatory.
For Lokesh Jindal, head of products and marketing at Axtria, a driving factor holding companies back from scaling agentic AI is that the technology does not behave in the same way that we have come to expect from traditional enterprise software.
“Ultimately, everything is based on a large language model (LLM),” he says. “And an LLM is by its very nature a probabilistic model. It is not a deterministic model.”
To the average AI user, that distinction may sound academic, but in practice, it has significant consequences for deployment. Whereas traditional enterprise software is designed to operate in a more black-and-white realm of fixed rules and identical results, LLMs work in what Jindal describes as “shades of grey.” Simply put, these models use statistical inference to estimate the most likely outcome. Consequently, the margin for error never completely disappears.
In a pilot, these limitations can be managed, but scale changes that equation.
“A pilot does not give you that exposure,” he says. “You can make it perfect for that controlled environment, but then when you try to put it into production, the environment is not that controlled anymore.”
The issue, he explains, is that many organisations still approach AI as if it should behave like traditional enterprise software. But expecting deterministic behaviour from a probabilistic system creates a gap between what the technology can realistically deliver and what businesses believe they are buying.
“We always asked for commitment of 99.9% accuracy, and suddenly we are saying 94%, 95% is okay,” he explains. “In pilots, fantastic, but the moment you try to scale, and you now get more complexity, the probability kicks in, and it's not acceptable in production.”
It is in that initial mismatch that many pilots are ultimately doomed to fail.
Scaling begins with foundations
Much of the conversation around AI, in all its forms, has centred on models. Which one is most accurate? Which is most powerful? However, organisations looking to scale beyond the pilot stage often struggle with a question much closer to home: is the data I am feeding into that model fit for purpose?
Rajesh Choudhary, who leads Axtria's Agentic AI Centre of Excellence, argues that this is where many organisations begin to run into trouble.
"The primary reason for data challenges is that every organisation is using analytics-ready data, and they are trying to put AI projects on top of that," he says. "But there is a fundamental disconnect, because the way you prepare data for analytics is different."
He likens that difference to the contrast between reheating a prepared meal and cooking from scratch.
Traditional analytics, he explains, resembles a microwave. The calculations have already been performed, and the metrics already exist. The system simply retrieves the answers that have been prepared in advance. Agentic AI, by contrast, is more like preparing a meal in a live kitchen. In order to deliver a high-quality result, you need access to far richer information than a conventional reporting environment was ever designed to provide.
Increasingly, he explains, that missing ingredient is context.
Connecting an AI agent to enterprise data is now fairly straightforward. Teaching it how different datasets relate to one another, how commercial teams use that information, and what business rules should guide its decision-making, remains considerably more challenging.
Choudhary describes this process as building a “context layer”. In essence, he explains, this acts as an organisational guidebook, helping an agent understand both where information resides and how it fits into the company’s bigger structural picture. Without this additional layer, even the most sophisticated model will struggle to move beyond surface-level responses.
Of course, in order to trust the output created by agentic AI, it is important that users are able to understand how an answer was produced. Enterprise users increasingly expect AI to show its reasoning, revealing which sources were used, how information was connected, and why a particular conclusion was reached.
“We are enabling what is called context transparency, which is where you got the answer, but you also are given a complete grounding summary that this is how we were able to give you an answer,” explains Choudhary.
"It's not just what's the answer," he says. "Show your scratchpad. Where did you do this calculation?"
Scaling is a redesign
It’s tempting to assume that the majority of organisations that struggle to scale AI do so because the technology itself is still maturing. But, as Axtria’s experts highlight, the biggest barrier holding companies back may have nothing to do with technology at all.
“Most pilots that fail tend to be isolated experiments.”
Pharma companies have spent decades organising themselves into systems of specialist functions, each with their own priorities, budgets, and ways of operating. AI did not create these siloes, but it has exposed them.
"In my opinion, most pilots that fail tend to be isolated experiments," explains Sameer Sardana, product management principal at Axtria. "They prove a point in the little niche that the pilot was designed for, but don't, by design, try to solve the enterprise problem."
The nature of isolated pilots means that scaling can result in a patchwork of different, competing systems that reflect the same fragmented landscape that companies are trying to avoid. The only way to counter this, Sardana argues, is to invert the pyramid: see scale as a starting point, rather than the end goal.
Of course, this type of mindset shift doesn’t happen overnight. Users need time to understand where AI performs well, where human judgement remains essential, and ultimately how and where the two can work together.
“A large part of building that trust and building that confidence – apart from ensuring that we have done robust testing in the responses and figured out and worked out all different types of edge cases – is about managing change,” he says. “Instead of rolling out large-scale, high-impact decisions in the beginning, we start with rolling out simple decisions.”
Jindal argues that organisations often underestimate how long meaningful change takes. Technology may evolve in months, but people rarely do. Attempts to accelerate organisational change too aggressively risk creating resistance, rather than adoption. "You just have to keep at it," he says. "If you try to drive it too fast, you break things."
Seen through that lens, the challenge facing enterprise AI is no longer primarily technical. To join the likes of Axtria on the other side of pilot purgatory, organisations must be prepared to rethink the way that decisions are made, and ultimately how success is measured. For many companies, that may prove to be the longest journey of all.
About Axtria
Axtria helps life sciences companies harness the potential of data science and software to improve patient outcomes by connecting the right therapies to the right patients at the right time. The company is a leading global provider of award-winning cloud software and data analytics to the life sciences industry. We’re proud to deliver proven solutions that help pharmaceutical, medical device, and diagnostics companies complete their journey from data to insights to action, enabling them to earn superior returns on their investments. As a participant in the United Nations Global Compact, Axtria is committed to aligning strategies and operations with universal principles on human rights, labor, environment, and anti-corruption, and taking actions that advance societal goals.
About the interviewees
Lokesh Jindal is head of products at Axtria, where he directs product strategy and the development of enterprise-grade agentic platforms, including Axtria DataMAx, Axtria SalesIQ, Axtria MarketingIQ, and Axtria HIQ. He brings more than three decades of experience across global technology firms and entrepreneurial ventures. Under his leadership, Axtria now supports 18 of the top 20 global pharma companies in data-driven commercial decision-making. Jindal writes and speaks on generative and agentic AI in regulated industries. At Axtria, he also leads marketing, and oversees cyber security and AI adoption strategy. Prior to Axtria, he helped move the enterprise software market from on-premises systems to cloud architectures, and he brings that same perspective to the shift towards agentic AI. He has held senior leadership roles at CA Technologies, co-founded start-ups, and advises growth-stage companies. He holds an MBA from INSEAD, an MBA in Finance and Marketing from XLRI Jamshedpur, and a B.Tech in Electrical Engineering from IIT Delhi.
Rajesh Choudhary is a principal of AI and data products at Axtria, where he builds Axtria InsightsMAx.ai and agentic solutions for commercial pharma. His work covers agent-ready data products, AI context services, and end-to-end AgentOps, scaling data products and reporting through data agents and generative BI. At Axtria, he has held senior roles across data science, AI, and cloud data solutions, and brings more than 18 years of experience building pharma commercial intelligence. Before Axtria, Choudhary held architecture and engineering leadership roles at Optum, Mahindra Satyam, and Cognizant, spanning data warehousing, big data platforms, and BI delivery across healthcare, telecom, and financial services. He speaks regularly at industry forums, including PMSA annual conferences and the Databricks Data + AI Summit, on enterprise context foundations and agentic AI in commercial life sciences. He holds an Executive Graduate Business Management qualification from IIM Lucknow and a Bachelor of Computer Applications from IGNOU.
Sameer Sardana is a principal of product management at Axtria, where he leads strategy, development, and go-to-market for the company's SaaS and data products in life sciences commercial. He has taken three net-new platforms from concept to launch, working with engineering, marketing, and commercial teams to reach first release in under six months and building the investment case behind each. His product work spans customer engagement, promotional measurement, and MLOps, including next best action engines, personalised channel and content strategy, and journey design for top pharma companies. During his time with Axtria, Sardana led relationships with Top-20 pharma clients, covering analytics, commercial operations, and digital transformation. His experience spans incentive compensation, sales force alignment, targeting and call planning, and commercial model design. He holds an MTech in Process Engineering and Design and a BTech in Chemical Engineering, both from IIT Delhi.
Supercharge your pharma insights: Sign up to pharmaphorum's newsletter for daily updates, weekly roundups, and in-depth analysis across all industry sectors.
Want to go deeper?
Continue your journey with these related reads from across pharmaphorum
Click on either of the images below for more articles from this edition of Deep Dive: AI 2026
